TrialLower urinary tract symptoms2020

Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study.

Takao Katoh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.